PMC:7405836 / 107150-107482 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T16","span":{"begin":44,"end":47},"obj":"Body_part"},{"id":"T17","span":{"begin":58,"end":61},"obj":"Body_part"}],"attributes":[{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":"A molecular docking study, conducted in the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 using different commercially available antipolymerase drugs, identified that drugs such as ribavirin, remdesivir, galidesivir, tenofovir, and sofosbuvir bind RdRp tightly, indicating their vast potential to be used against COVID-19 (305)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T961","span":{"begin":83,"end":91},"obj":"Disease"},{"id":"T962","span":{"begin":83,"end":87},"obj":"Disease"},{"id":"T963","span":{"begin":317,"end":325},"obj":"Disease"}],"attributes":[{"id":"A961","pred":"mondo_id","subj":"T961","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A962","pred":"mondo_id","subj":"T962","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A963","pred":"mondo_id","subj":"T963","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"A molecular docking study, conducted in the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 using different commercially available antipolymerase drugs, identified that drugs such as ribavirin, remdesivir, galidesivir, tenofovir, and sofosbuvir bind RdRp tightly, indicating their vast potential to be used against COVID-19 (305)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T41","span":{"begin":0,"end":1},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"A molecular docking study, conducted in the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 using different commercially available antipolymerase drugs, identified that drugs such as ribavirin, remdesivir, galidesivir, tenofovir, and sofosbuvir bind RdRp tightly, indicating their vast potential to be used against COVID-19 (305)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T55497","span":{"begin":148,"end":153},"obj":"Chemical"},{"id":"T4016","span":{"begin":171,"end":176},"obj":"Chemical"},{"id":"T20220","span":{"begin":185,"end":194},"obj":"Chemical"},{"id":"T83488","span":{"begin":196,"end":206},"obj":"Chemical"},{"id":"T98290","span":{"begin":221,"end":230},"obj":"Chemical"},{"id":"T9706","span":{"begin":236,"end":246},"obj":"Chemical"}],"attributes":[{"id":"A73729","pred":"chebi_id","subj":"T55497","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A66079","pred":"chebi_id","subj":"T4016","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A44528","pred":"chebi_id","subj":"T20220","obj":"http://purl.obolibrary.org/obo/CHEBI_63580"},{"id":"A38617","pred":"chebi_id","subj":"T83488","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A5533","pred":"chebi_id","subj":"T98290","obj":"http://purl.obolibrary.org/obo/CHEBI_134504"},{"id":"A97101","pred":"chebi_id","subj":"T98290","obj":"http://purl.obolibrary.org/obo/CHEBI_63625"},{"id":"A37062","pred":"chebi_id","subj":"T98290","obj":"http://purl.obolibrary.org/obo/CHEBI_63716"},{"id":"A85587","pred":"chebi_id","subj":"T9706","obj":"http://purl.obolibrary.org/obo/CHEBI_85083"}],"text":"A molecular docking study, conducted in the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 using different commercially available antipolymerase drugs, identified that drugs such as ribavirin, remdesivir, galidesivir, tenofovir, and sofosbuvir bind RdRp tightly, indicating their vast potential to be used against COVID-19 (305)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T732","span":{"begin":0,"end":332},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"A molecular docking study, conducted in the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 using different commercially available antipolymerase drugs, identified that drugs such as ribavirin, remdesivir, galidesivir, tenofovir, and sofosbuvir bind RdRp tightly, indicating their vast potential to be used against COVID-19 (305)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2906","span":{"begin":74,"end":78},"obj":"Gene"},{"id":"2907","span":{"begin":252,"end":256},"obj":"Gene"},{"id":"2908","span":{"begin":83,"end":93},"obj":"Species"},{"id":"2914","span":{"begin":185,"end":194},"obj":"Chemical"},{"id":"2915","span":{"begin":196,"end":206},"obj":"Chemical"},{"id":"2916","span":{"begin":208,"end":219},"obj":"Chemical"},{"id":"2917","span":{"begin":221,"end":230},"obj":"Chemical"},{"id":"2918","span":{"begin":236,"end":246},"obj":"Chemical"},{"id":"2923","span":{"begin":317,"end":325},"obj":"Disease"}],"attributes":[{"id":"A2906","pred":"tao:has_database_id","subj":"2906","obj":"Gene:43740578"},{"id":"A2907","pred":"tao:has_database_id","subj":"2907","obj":"Gene:43740578"},{"id":"A2908","pred":"tao:has_database_id","subj":"2908","obj":"Tax:2697049"},{"id":"A2914","pred":"tao:has_database_id","subj":"2914","obj":"MESH:D012254"},{"id":"A2915","pred":"tao:has_database_id","subj":"2915","obj":"MESH:C000606551"},{"id":"A2916","pred":"tao:has_database_id","subj":"2916","obj":"MESH:C517546"},{"id":"A2917","pred":"tao:has_database_id","subj":"2917","obj":"MESH:D000068698"},{"id":"A2918","pred":"tao:has_database_id","subj":"2918","obj":"MESH:D000069474"},{"id":"A2923","pred":"tao:has_database_id","subj":"2923","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"A molecular docking study, conducted in the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 using different commercially available antipolymerase drugs, identified that drugs such as ribavirin, remdesivir, galidesivir, tenofovir, and sofosbuvir bind RdRp tightly, indicating their vast potential to be used against COVID-19 (305)."}